You are here:
darunavir (Prezista)
Advice
following a full submission:
darunavir (Prezista®) 400mg is accepted for use within NHS Scotland.
Indication under review: darunavir 800mg once daily co-administered with low dose ritonavir (100mg once daily) for the treatment of HIV-1 infection in antiretroviral therapy experienced adults with no darunavir resistance associated mutations and who have plasma HIV-1 RNA <100,000 copies/mL and CD4+ cell count ≥100 cells/mm3.
Darunavir 800mg/ritonavir 100mg once daily was demonstrated to be non inferior to darunavir 600mg/ritonavir 100mg twice daily, when administered with an optimised background regimen that consisted of at least two nucleoside
Drug Details
| Drug Name: | darunavir (Prezista) |
|---|---|
| SMC Drug ID: | 707/11 |
| Manufacturer: | Janssen-Cilag Ltd |
| Indication: | For the treatment of HIV-1 infection in antiretroviral therapy (ART) experienced adults |
| BNF Category: | |
| Sub Category: | 5.3 Antiviral Drugs |
| Submission Type: | Full submission |
| Status: | Accepted |
| Date Advice Published: | 8 August 2011 |